Lukas Rindlisbacher

Publication Activity (10 Years)

Years Active: 2023-2023
Publications (10 Years): 3

Top Topics

Prognostic Factors

Ejection Fraction

Induced Apoptosis

Top Venues

Molecular cancer research : MCR

Science translational medicine

Science immunology

This page only lists publications with an associated author ORCID identifier.

Publications

Marlene Langenbach, Sophie Giesler, Stefan Richtsfeld, Sara Costa-Pereira, Lukas Rindlisbacher, Tobias Wertheimer, Lukas M Braun, Geoffroy Andrieux, Sandra Duquesne, Dietmar Pfeifer, Nadine M Woessner, Hans D Menssen, Sanaz Taromi, Justus Duyster, Melanie Börries, Tilman Brummer, Bruce R Blazar, Susana Minguet, Patrick Turko, Mitchell Paul Levesque, Burkhard Becher, Robert Zeiser
MDM2 inhibition enhances immune checkpoint inhibitor efficacy by increasing IL-15 and MHC class II production. Molecular cancer research : MCR (2023)
Sonja Marinović, Maja Lenartić, Karlo Mladenić, Marko Šestan, Inga Kavazović, Ante Benić, Mia Krapić, Lukas Rindlisbacher, Maja Cokarić Brdov Ak, Colin Sparano, Gioana Litscher, Tamara Turk Wensveen, Ivana Mikolašević, Dora Fǔkar Čupić, Lidija Bilić-Zulle, Aleksander Steinle, Esther Von Stebut, Adrian C Hayday, Sonia Tugues, Burkhard Becher, Bojan Polic, Felix M Wensveen
NKG2D-mediated detection of metabolically stressed hepatocytes by innate-like T cells is essential for initiation of NASH and fibrosis. Science immunology 8 (87) (2023)
Thomas Look, Emanuele Puca, Marcel Bühler, Daniel Kirschenbaum, Roberto De Luca, Riccardo Stucchi, Domenico Ravazza, Cesare Di Nitto, Patrick Roth, Yonatan Katzenelenbogen, Assaf Weiner, Lukas Rindlisbacher, Burkhard Becher, Bjørt K Kragesteen, Michael Weller, Dario Neri, Teresa Hemmerle, Tobias Weiss
Targeted delivery of tumor necrosis factor in combination with CCNU induces a T cell-dependent regression of glioblastoma. Science translational medicine 15 (697) (2023)